Efficacy and safety or tirzepatide once weekly in participants with type 2 diabetes who have obesity or are overweight: A randomised, double-blind, placebo-controlled trial (SURMOUNT-2)

Eli Lilly and Company India Pvt Ltd0 个研究点目标入组 26 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•1. Have Type 2 Diabetes (T2DM) with HbA1c =7% to =10% at screening, on stable therapy for the last 3 months prior to screening. T2DM may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or glucagon like peptide-1 receptor agonists (GLP-1 RAs)
•2. Have a BMI of =27 kg/m²
•3. Are overweight or have obesity
•4. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
•5. Are at least 18 years of age and age of majority per local laws and regulations

•1. Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except T2DM
•2. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values >270 mg/dL(on 2 nonconsecutive days) prior to Visit 3
•3. Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
•4. Have self-reported change in body weight >5kg within 3 months prior to screening
•5. Have had a history of chronic or acute pancreatitis
•6. Change in body weight greater than 5 kg within 3 months prior to starting study
•7. Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
•8. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
•9. History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
•10. Any lifetime history of a suicide attempt

发起方

Eli Lilly and Company India Pvt Ltd